324 related articles for article (PubMed ID: 32711117)
1. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
[TBL] [Abstract][Full Text] [Related]
2. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
[TBL] [Abstract][Full Text] [Related]
3. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
[TBL] [Abstract][Full Text] [Related]
4. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
[TBL] [Abstract][Full Text] [Related]
5. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
Tang CH; Yu F; Huang CY; Chen DY
Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
[TBL] [Abstract][Full Text] [Related]
6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
8. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study.
Dormuth CR; Fisher A; Hudson M; Austin PC; Ernst P; Bresee L; Chateau D; Tamim H; Paterson JM; Lafrance JP; Taylor-Gjevre RM; Platt RW; Canadian Network For Observational Drug Effect Studies Cnodes Investigators
Semin Arthritis Rheum; 2021 Dec; 51(6):1291-1299. PubMed ID: 34462128
[TBL] [Abstract][Full Text] [Related]
9. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
12. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
13. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
[TBL] [Abstract][Full Text] [Related]
14. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with biologic agents in rheumatic diseases: current and future prospects.
Inui K; Koike T
Ther Adv Musculoskelet Dis; 2016 Oct; 8(5):192-202. PubMed ID: 27721905
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH
Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231
[TBL] [Abstract][Full Text] [Related]
17. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
18. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
